Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
cd47 save search
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Published: 2023-11-03 (Crawled : 20:00) - globenewswire.com
KA 4 | $0.6648 4.71% 4.5% 310K
|
Manufacturing
| Email alert
Add to watchlist
cd27 antibody preclinical immunotherapy meeting
Embattled Researchers See Path Forward for Anti-CD47 Cancer Drugs
Published: 2023-10-30 (Crawled : 05:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 3.28%
H: 5.56%
C: 2.38%
cd47 cancer
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023
Published: 2023-10-12 (Crawled : 14:00) - globenewswire.com
KA 4 | $0.6648 4.71% 4.5% 310K
|
Manufacturing
|
| O: 1.1%
H: 24.59%
C: -0.27%
kva1212 antibody agonist cancer immunotherapy
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
KA 4 | $0.6648 4.71% 4.5% 310K
|
Manufacturing
|
| O: -28.1%
H: 26.76%
C: 22.36%
cd27 conference antibody agonist tumor preclinical immunotherapy immunology
AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.83%
H: 5.79%
C: 5.79%
cd47 abbvie antibody deal
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
Published: 2023-09-25 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.83%
H: 5.79%
C: 5.79%
cd47 partnership abbvie antibody
Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
KA 4 | $0.6648 4.71% 4.5% 310K
|
Manufacturing
|
| O: 1.74%
H: 10.68%
C: 6.41%
cd27 conference antibody agonist tumor preclinical immunotherapy immunology
ALX Oncology Axes Two CD47 Programs on Disappointing Results
Published: 2023-08-11 (Crawled : 23:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: -1.57%
H: 3.39%
C: 1.2%
cd47 axes results
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Published: 2023-06-12 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.02%
H: 0.19%
C: -0.19%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.2%
H: 1.57%
C: 1.54%
ibi322 treatment meeting
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
Published: 2023-04-24 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: -1.49%
H: 1.51%
C: -3.64%
cd47 antibody china study
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 04:20) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ibi188 meeting phase 2b
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Published: 2022-11-03 (Crawled : 13:20) - biospace.com/
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: -3.04%
H: 2.72%
C: 2.51%
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: -2.47%
H: 6.18%
C: 4.21%
cd47 antibody
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: -1.22%
H: 2.67%
C: -2.48%
cd47 antibody cd73
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.17%
H: 0.68%
C: -5.57%
cd47 antibody presentation phase 2
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 1.12%
H: 6.39%
C: 2.76%
cd47 antibody phase 2
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China
Published: 2022-07-15 (Crawled : 09:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K
|
Health Technology
|
| O: -1.29%
H: 1.62%
C: 0.62%
cd47 antibody trial
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Published: 2022-06-13 (Crawled : 22:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -2.45%
H: 1.11%
C: -1.44%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: -7.83%
H: 1.49%
C: -1.7%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
tti-622 monjuvi collaboration trial cd47
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 3.85%
H: 1.67%
C: -2.04%
cd47 preclinical immunotherapy pre-clinical her2- her2
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
Published: 2022-01-05 (Crawled : 13:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 0.0%
H: 1.34%
C: -7.45%
cd47 als research immunotherapy therapy collaboration iot
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.